[Hye-Kyung Chang, Yeong-Soo Oh, Cheol-Won Park, Yong-Jin Jang, Tae-Kyo Park, Sung-Sub Kim, Min-Jung Kim, Mi-Jeong Park, Jung-Gyu Park, Hee-Dong Park, Kyeong-Sik Min, Tae-Soo Lee, Sang-Kyun Lee, Soo-Hyeon Kim, Hee-Kyung Jeong, Sun-Hwa Lee, Hwa-Dong Kim, Ae-Ri Kim, Ki-Sook Park, Hyun-Ik Shin, Hyeong-Wook Choi, Kyu-Woong Lee, Jae-Hoon Lee, Tae-Ho Heo, Ho-Jun Kim, Tae-Sik Kwon] KR Daejeon The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same

[CHANG, Hye-Kyung, OH, Yeong-Soo, PARK, Cheol-Won, JANG, Yong-Jin, PARK, Tae-Kyo, KIM, Sung-Sub, KIM, Min-Jung, PARK, Mi-Jeong, PARK, Jung-Gyu, PARK, Hee-Dong, MIN, Kyeong-Sik, LEE, Tae-Soo, LEE, Sang-Kyun, KIM, Soo-Hyeon, JEONG, Hee-Kyung, LEE, Sun-Hwa, KIM, Hwa-Dong, KIM, Ae-Ri, PARK, Ki-Sook, SHIN, Hyun-Ik, CHOI, Hyeong-Wook, LEE, Kyu-Woong, LEE, Jae-Hoon, HEO, Tae-Ho, KIM, Ho-Jun, KWON, Tae-Sik] LG TWIN TOWER, EAST TOWER 20 YOIDO-DONG, YOUNGDEUNGPO-GU SEOUL 150-010;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to an isoxazoline derivative as an inhibitor against various caspases, a process for preparing the same, and a therapeutic composition for preventing inflammation and apoptosis comprising the same

[CHANG, Hye-Kyung, OH, Yeong-Soo, PARK, Cheol-Won, JANG, Yong-Jin, KIM, Sung-Sub, KIM, Min-Jung, PARK, Mi-Jeong, PARK, Jung-Gyu, LEE, Sun-Hwa, PARK, Hee-Dong, KIM, Ae-Ri, PARK, Ki-Sook, MIN, Kyeong-Sik, LEE, Tae-Soo] LG Twin Tower, East Tower 20, Yoido-dong Youngdeungpo-gu Seoul 150-010;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to a compound of the formula (1), pharmaceutically acceptable salt, physiologically hydrolysable ester, hydrate, solvate, or steroisomer thereof having inhibitory activity against caspases. The compound contains unknown new 2-alkyl-4-oxobutanoyl group. Further, the present invention relates to a process for preparing the compound of formula 1 and a method for determining its binding ability for caspases. The compound of formula 1 can be used effectively for the treatment or relief of various diseases caused by caspases.

[PARK, Ki Sook, LEE, Su Hyon, HWANG, Ji Hoon, PARK, Chan Woong] 6F STC B/D, Nonhyun-Dong, Gangnam-gu Seoul 135-010;#124-1804 Doosan Apt., Seokgwan-dong, Seongbuk-gu Seoul 136-150;1010-17, Sadang 1-dong, Dongjak-gu Seoul 156-091;Jicheungwoo, 46-10, Guui 2-dong, Gwangjin-gu Seoul 143-202;#b-805 Miseong Apt., Yeouido-dong, Yeongdeungpo-gu Seoul 150-010 The present invention relates to a pharmaceutical composition for cell therapy of pigmentation disorders, which comprises as an active ingredient (a) melanocytes and keratinocytes, or (b) melanocytes and fibroblasts. The cell therapy composition of this invention allows for the first time to treat pigmentation disorders through cell therapy regimen. The present composition comprises as active ingredients a mixed cell preparation of melanocytes and keratinocytes or a mixed cell preparation of melanocytes and fibroblasts such that it induces very effectively pigmentation to treat diseases associated with hypopig mentation such as vitiligo.

[AHN YONG HO, CHOI KANG YEOL, KIM HO GEUN, PARK KI SOOK] KR;KR;KR;KR PURPOSE: A method and reagent for the early diagnosis of large intestine cancer by measuring MAP kinase or MEK activity in the doubtful tissue having a doubt of a cancer and normal tissue and using as a mark of the early diagnosis in a case its enzyme activity is lowered as compared to normal tissue are provided, which can be applied to diagnose the recurrence of cancer after the treatment of cancer. CONSTITUTION: This reagent for the early diagnosis of large intestine cancer contains (a)a phospho-ERK1/2 polychlonal antibody capable of measuring MEK activity and (b)a secondary antibody such as anti-rabbit immune globulin G goat, wherein a coloring reagent used for coloring the secondary antibody contains 3-aminophthalate, hydrogen peroxide reacting with 3-aminophthalate and 4-indophenol as a reaction accelerating agent.

[SHIN, Hyun Ik, CHOI, Hyeong Wook, HEO, Tae Ho, LEE, Kyu Woong, LEE, Jae Hoon, PARK, Ki Sook] LG Twin Tower, East Tower 20, Yoido-dong, Youngdeungpo-gu Seoul 150-010;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to an isoxazoline derivative having the cyclic carboxylic acid hemiketal moiety of formula (1) for use as caspase inhibitor, a process for preparing it, and a pharmaceutical composition comprising it.

[PARK, Ki Sook, YUN, Jung Min, KIM, Bong Chan, KIM, Kyu Young, LEE, Ji Hye] LG Gwanghwamun Bldg. 92, Sinmunno 2-ga, Jongno-gu Seoul 110-062;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.

[YUN, Jung Min, PARK, Ki Sook, YOON, Joo Yong, LEE, Ju Young, KIM, Geun Tae, JUNG, Cheol Kyu] LG Gwanghwamun Bldg. 92, Sinmunno 2-ga, Jongno-gu Seoul 110-062;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R&D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to a crystalline form of the compound of formula (1), and a process for preparing the same.

[LEE, Ji Hye, PARK, Ki Sook, YUN, Jung Min] LG Twin Tower, East Tower 20, Yoido-dong, Youngdeungpo-gu Seoul 150-010;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380;R & D Park, LG Life Sciences Ltd. 104-1, Moongi-dong, Yuseong-gu Daejeon 305-380 The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl} oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same.

[PARK KI SOOK] KR The present invention relates to a coupling structure of a bracelet. More specifically, a male fixing unit with a plate spring is arranged on an end of a first body to prevent a bracelet consisting of the first body rotated by a first hinge and a second body from being separated by an external force regardless of the will of a user while the bracelet is coupled to the wrist of the user. A stopping end is formed on an upper portion of the plate spring to be inserted into an opened end of the second body. The second body has a stopper on an opened upper portion thereof to be stopped on the stopping end to promote firm coupling. The user presses a pressing part to press the plate spring to take off the bracelet to bend the plate spring to allow the stopping end to press the plate spring downwards to promote easy removal to improve wearability. The second body has an auxiliary stopping part which is arranged on one side near a surface thereof coming in contact with the first body, is rotated by a second hinge, and has a stopping protrusion formed on a free end thereof to be seated on a stopping groove formed on a lower side of the plate spring to promote secondary fixing. The second body includes an upper fixing plate on an upper portion and a lower fixing plate on a lower portion around a fixing body on one side of the outer circumference near the surface thereof coming in contact with the first body to be prevented from being separated from the second body. An elastic spring is formed on an upper side of the lower fixing plate and a lower side of the inner circumferential surface of the second body. A fixing body with a fixing part is formed on a lower side of the lower fixing plate. The fixing part is stopped on a fixing groove formed on an upper surface of the plate spring to promote tertiary coupling.